5 min read
Trial Tuesday: On The Front Line
Genmab halves the risk of death in head and neck cancer, the KRAS G12C frontline race heats up, GSK breaks an osteosarcoma drought, and Vanda targets GLP-1 nausea.
Genmab halves the risk of death in head and neck cancer, the KRAS G12C frontline race heats up, GSK breaks an osteosarcoma drought, and Vanda targets GLP-1 nausea.